Edition:
United States

CTi Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

4.29USD
4:00pm EDT
Change (% chg)

$0.13 (+3.12%)
Prev Close
$4.16
Open
$4.22
Day's High
$4.34
Day's Low
$4.22
Volume
7,408
Avg. Vol
37,377
52-wk High
$6.42
52-wk Low
$3.08

Latest Key Developments (Source: Significant Developments)

CTI Biopharma Q4 loss per share $0.23
Thursday, 2 Mar 2017 04:01pm EST 

Cti Biopharma Corp : Cti biopharma reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.23 .Total revenues for q4 $9.1 million compared to $11.3 million.  Full Article

CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting
Monday, 21 Nov 2016 04:01pm EST 

CTi Biopharma Corp :CTi Biopharma announces phase 3 data from the PERSIST-2 trial of Pacritinib to be presented in late-breaking session at ASH annual meeting.  Full Article

CTI BioPharma announces retirement of president and CEO
Monday, 3 Oct 2016 01:30am EDT 

CTI BioPharma Corp : James Bianco,CTI BioPharma's president and chief executive officer, has retired from company . CTI BioPharma announces retirement of president and CEO .Richard Love, a director of CTI BioPharma since 2007, has been appointed to serve as interim president and CEO.  Full Article

CTi biopharma granted 180 day extension by NASDAQ to regain compliance
Thursday, 22 Sep 2016 01:30am EDT 

CTi Biopharma Corp : CTi Biopharma granted 180 day extension by NASDAQ to regain compliance with minimum bid price rule .On September 20, 2016, NASDAQ listing qualifications granted co until March 20, 2017, regain compliance with minimum bid price rule.  Full Article

CTI Biopharma Q2 loss per share $0.07
Thursday, 4 Aug 2016 04:01pm EDT 

CTI Biopharma Corp : Q2 loss per share $0.07 . CTI Biopharma reports second quarter 2016 financial results .Total revenues for q2 ended june 30, 2016, were $7.4 million versus $1.1 million.  Full Article

CTi Biopharma says Persist-1 phase 3 trial met its primary endpoint
Tuesday, 7 Jun 2016 01:30am EDT 

CTi Biopharma Corp : Says announced long-term safety and efficacy results from pivotal phase 3 Persist-1 trial . Says Persist-1 trial met its primary endpoint . Says results represent an update on efficacy and safety for all patients regardless of their initial platelet count . Patients who crossed over to Pacritinib experienced reductions in spleen volume as patients initially randomized to Pacritinib . Responses to Pacritinib were durable and rates of 35 percent or greater spleen volume reduction were maintained from weeks 24 to 72 . Most frequently occurring adverse events with Pacritinib were gastrointestinal events and incidence decreased over time .Says patients treated with Pacritinib had stable mean platelet counts and hemoglobin levels through week 72.  Full Article

CTI Biopharma Q1 earnings per share $0.01
Tuesday, 10 May 2016 04:58pm EDT 

CTI Biopharma Corp : CTI Biopharma reports first quarter 2016 financial results . Q1 earnings per share $0.01 .Q1 revenue $36.5 million versus $2.7 million.  Full Article

CTI BioPharma Corp prices underwritten public offering of $55 mln of convertible preferred Stock
Friday, 4 Dec 2015 11:15am EST 

CTI BioPharma Corp:Says pricing of an underwritten public offering of 55,000 shares of its Series N-2 Preferred Stock, offered at a price to the public of $1,000 per share of Series N-2 Preferred Stock.Says each share of Series N-2 Preferred Stock is convertible at option of the holder, at any time subject to certain limitations, into shares of our common stock at a conversion price of $1.10 per share of common stock, for a total of approximately 50,000,000 shares of common stock.  Full Article

CTI BioPharma Corp announces proposed public offering of convertible preferred stock
Thursday, 3 Dec 2015 04:31pm EST 

CTI BioPharma Corp:Announces proposed public offering of convertible preferred stock.Each share of series n-2 preferred stock will have a stated value of $1,000 per share.To use net proceeds for launch of pacritinib in U.S., to conduct additional research for application of pacritinib.To also use net proceeds to advance commercialization of pixuvri, for development of tosedostat in registration-directed trials.  Full Article

CTI BioPharma Corp lowers FY 2015 revenue guidance; reaffirms FY 2015 Non-GAAP operating loss guidance
Thursday, 5 Nov 2015 04:01pm EST 

CTI BioPharma Corp:Expects total revenues for FY 2015 will be approximately $30 million to $45 million.Expects Non-GAAP operating loss for FY 2015 will be approximately $75 million to $85 million.FY 2015 revenue of $51 million and EBIT of $(77) million - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-CTI Biopharma Q4 loss per share $0.23

* Cti biopharma reports fourth quarter and full year 2016 financial results